A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells. A2 Bio has three Investigational New Drugs (INDs) in a truly first in human clinical stage personalized cell therapy studies EVEREST-1, EVEREST-2 and DENALI-1 with a 4th master pre-screening study BASECAMP-1 to identify and triage patients to both the Auto and Allogeneic Tmod cell therapy studies.  For more information, please visit the company’s website at